TACSTD2 and breast cancer: Because TROP2 is expressed in more than 90% of breast cancers, no biomarker pre-screening was required in the TROPiCS-02 trial of SG, in contrast to the anti-HER2 antibodies for which HER2 screening is mandatory [52].